Is Your Paper Ready for Cancer Letters? A Pre-Submission Readiness Check

These are the current, public submission facts and fees that bear on readiness. Confirm them on the journal's own guide for authors before you submit, since Elsevier's open-access schedule and article-type rules change.

Source: Cancer Letters aims and scope and guide for authors (ScienceDirect, Elsevier), Elsevier open-access pricing, and the LetPub journal selector (accessed June 2026). Selectivity figures are estimates from journal-selector data; verify the live APC and article-type rules before submitting.

The headline that matters for readiness: the desk decision is fast, and the bar is mechanistic. The journal does not return papers for a missing checklist the way a clinical journal does. It returns them because the abstract reports what was observed without naming the cancer-biology mechanism, or because the central claim rests on correlation. Treat the mechanism-shown-not-inferred test as gating, not as polish.

Cancer Letters screens for mechanistic depth and translational relevance at desk, fast, before any peer reviewer sees the paper. Each named rejection pattern below maps to a specific triage tell, and editors reject for these before peer review begins. Editors screen first for the mechanism-shown-not-inferred test, then for whether the functional and in vivo validation is present, not buried.

Correlative expression data presented as a finding. The most common fast return. The manuscript shows that a gene is differentially expressed, correlates with stage or survival, and sits in a known pathway, then stops. There is no perturbation, no phenotype measured after perturbation, and no rescue. To the desk, this is a starting point dressed as a conclusion, and it is the first thing to test on your own abstract.

Single-cell-line mechanism with no second model or rescue. A clean knockdown in one cell line that changes a phenotype is suggestive, not causal. Without a rescue and a second model, the result reads as possibly cell-line-specific or off-target, and an editor who has seen the pattern thousands of times returns it rather than sending three reviewers to ask for the same two experiments.

In vitro-only data for an in vivo claim. When the abstract claims an effect on tumor growth or metastasis but every experiment is in a dish, the mismatch is visible immediately. The fix is an animal model that tests the actual claim, not more in vitro assays around it.

Mechanism inferred, not shown. An abstract that says a factor "may regulate" or "is associated with" a cancer phenotype, rather than "drives" it through a tested pathway, reads as descriptive. Cancer Letters editors notice the difference between "we observed" and "we demonstrate, and rescue confirms."

Scope drift: cell biology wearing an oncology label. Solid molecular cell biology that uses a tumor cell line as a convenient system, with no cancer-specific mechanism, is a fit return. The science can be sound and still be the wrong journal.

Walk each manuscript component before you submit. The order below mirrors what a Cancer Letters editor reads first.

Cover letter. Not a summary of the abstract. One sentence that states the causal cancer-biology mechanism and its translational implication. This is where the mechanistic case is won or lost.

Title and abstract. The abstract must name the mechanism causally and signal the functional and in vivo evidence early. If an editor cannot tell from the abstract alone whether the mechanism was shown or inferred, the paper reads as descriptive and is not ready.

Methods and statistical analysis. Perturbation, rescue, and the second model must be described clearly, with biological replicates, the statistical test stated, and effect sizes that match the claim. Hidden or underpowered functional experiments are a frequent weakness.

Figures and tables. Lead with the functional and in vivo figures that carry the mechanism. A paper whose main figures are expression heatmaps and survival curves, with the perturbation and rescue buried in later panels or the supplement, reads as a descriptive story.

Controls. Specificity controls for knockdowns and knockouts, rescue controls, validated antibodies, and the obvious off-target and confounder checks. These are the experiments reviewers always request; supplying them up front shortens review.

Supplementary material. Supporting, not load-bearing. If the in vivo result that proves your claim lives only in the supplement, promote it to the main text before you submit.

Data availability. Deposit sequencing or omics data in an appropriate repository with an accession number, and state it. Cancer-biology reviewers increasingly check this.

References. Recent and complete, citing the functional and translational literature your mechanism builds on rather than padding the introduction.

If you want a manuscript-specific signal across all of these components before you submit, run a free readiness scan.

If the readiness check says the paper is sound but not a Cancer Letters fit, route it deliberately rather than dropping a tier and blasting it out.

For a paper rejected on scope, Elsevier's Article Transfer Service can move the manuscript and any reviewer reports to a sister oncology journal without a full reformat. Accept a transfer only when the suggested journal genuinely fits your study type, not just because it is convenient.

In our pre-submission review work with Cancer Letters manuscripts, four readiness gaps separate papers that clear the mechanistic desk triage from those that come back within days. Across the cancer-biology manuscripts we have reviewed at Manusights, these four patterns account for most of the readiness flags we raise on oncology submissions, and three of the four are fixable before you submit. Recognizing which one applies to your paper is the difference between a clean submission and a wasted desk-rejection cycle.

The mechanism gap: correlation presented as causation. This is the readiness failure we see most often in Cancer Letters submissions. The dataset is solid and the analysis is clean, but the central evidence is correlative: a gene is differentially expressed, tracks with survival, and sits in a pathway, and the abstract treats that as the finding.

The tell is consistent: the abstract uses "is associated with" or "may regulate" rather than "drives," and no figure perturbs the proposed driver and rescues the phenotype. The fix is not new framing. It is the functional experiment, a loss-of-function plus rescue, that converts an association into a tested cancer-biology mechanism.

Across the Cancer Letters manuscripts we review at Manusights, the descriptive-versus-mechanistic split is the most frequently flagged readiness gap, ahead of validation breadth and figure order, and closing it changes more desk outcomes than any other single intervention.

The validation gap: single cell line, no second model, no in vivo. Cancer Letters editors return mechanistic claims that rest on one cell line and one perturbation. We repeatedly see manuscripts where a knockdown changes a phenotype in a single line, with no rescue and no second model, and where an in vivo claim is supported only by in vitro assays.

These are the exact two experiments reviewers ask for every time, so a desk editor often returns the paper rather than starting a review that will stall on predictable revisions. The right call before submission is to add the rescue and the second model, and an animal model when the claim is about tumor growth or metastasis.

The figure-order gap: descriptive data leading, functional data buried. We routinely flag manuscripts whose main figures are expression heatmaps, survival plots, and pathway diagrams, with the perturbation, rescue, and in vivo experiments pushed to the last panels or the supplement. To a cancer-biology editor, figure order is an argument: leading with descriptive data and hiding the functional evidence signals that the mechanistic story is not finished.

The fix is reordering, promoting the in vivo and rescue figures to the main text so the causal claim is visible in the first scroll.

The cover-letter gap: arguing the phenotype instead of the mechanism. Cancer Letters editors use the cover letter to judge fit before they read the manuscript. The weakest cover letters we see recite the methods and the headline phenotype and never state the causal mechanism or why it matters translationally.

A letter that says "we found that knockdown of X reduces proliferation" is not ready; one that says "we show that X drives metastasis through pathway Y, and rescue confirms the link, with in vivo validation" is. Same study, different framing, different desk outcome.

The practical takeaway: the mechanism, validation, and figure-order gaps are readiness fixes you make before submitting, and two of them require a real experiment, not a rewrite. The cover-letter gap is a framing fix. Our internal analysis of these submissions points to the same conclusion every time: at Cancer Letters, whether the mechanism is shown rather than inferred decides more desk outcomes than the polish of any single experiment.

Before you commit, a Cancer Letters mechanism and validation readiness check tests your manuscript against these exact gaps, so you find them before a desk editor does.